The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zhidkova I.A.

Kafedra nervnykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Karlov V.A.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Perampanel in pharmacotherapy of focal epilepsy: the efficacy and tolerability in routine clinical practice

Authors:

Zhidkova I.A., Karlov V.A., Vlasov P.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(9‑2): 82‑88

DOI: 10.17116/jnevro20161169282-88

Read: 4901 times

Download PDF (RU)
Contact the author
Table of contents

PERAMPANEL IN PHARMACOTHERAPY OF FOCAL EPILEPSY: THE EFFICACY AND TOLERABILITY IN ROUTINE CLINICAL PRACTICE
PERAMPANEL IN PHARMACOTHERAPY OF FOCAL EPILEPSY: THE EFFICACY AND TOLERABILITY IN ROUTINE CLINICAL PRACTICE

To cite this article:

Zhidkova IA, Karlov VA, Vlasov PN. Perampanel in pharmacotherapy of focal epilepsy: the efficacy and tolerability in routine clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(9‑2):82‑88. (In Russ.)
https://doi.org/10.17116/jnevro20161169282-88

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Brain microstructural abno­rmalities asse­ssed by diffusion kurtosis MRI in patients with focal temporal lobe epilepsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):171-177
Open obse­rvational study with a retrospective analysis of the effi­cacy and tole­rability of aceclofenac in patients with acute non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):99-105
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Effi­cacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79
Pera­mpanel treatment in IQSEC2-associated epileptic ence­phalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):143-149
Stereo-EEG-guided radiofrequency thermocoagulations in drug-resistant focal epilepsy. Burdenko's Journal of Neurosurgery. 2025;(3):7-16
Perioperative complications in surgery for craniosynostosis in children: a systematic review and meta-analysis. Burdenko's Journal of Neurosurgery. 2025;(3):114-121
Complications in diagnostic and therapeutic endo­scopic procedures on the lower gastrointestinal tract. Collegial discussion of info­rmed consent by the Asso­ciation of Quality Care Expe­rts. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):94-105
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Abstract:

Objective. To analyze the efficacy and tolerability of the innovative drug perampanel (PER) as add-on treatment of focal epilepsy in patients older than 12 years. Material and methods. Forty-six patients with focal epilepsy, aged from 12 to 63 years, mean age 31.7 years, were studied. Results and conclusion. A decrease in the frequency of all types of seizures by >50% was noted in 46,5% of patients. Stopping of all types of seizures was found in 25.6% of patients, i.e. in every fourth patient, stopping of secondary-generalized seizures in 39.5%. Adverse effects (AE) were identified in 13 (28.2%) of patients, including aggressiveness — 6 (13.0%); other AE were less frequent (<10%): sleepiness (8.7%), dizziness (4.3%), postural instability (4.3%), irritability (4.3%). PER was withdrawn in 3 (6.5%) patients due to AE. Mean effective dose was 6 mg/day. Quality-of-life improved in the majority of patients (71.7%).

Keywords:

perampanel
focal epilepsy
efficacy
tolerability
adverse events; side effects

Authors:

Zhidkova I.A.

Kafedra nervnykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta

Karlov V.A.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Vlasov P.N.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii", Moskva

Close metadata

References:

  1. Kwan P, Schachter S, Brodie M. Drug-Resistant Epilepsy. New England Journal of Medicine. 2011;365(10):919-926. doi: 10.1056/nejmra1004418
  2. Karlov VA. Epilepticheskii ochag, nervnaya set', pro- i antiepilepticheskie sistemy. Bolezni mozga — meditsinskie i sotsial'nye aspekty. Pod red. Guseva E.I., Gekht A.B. M.: 2016.
  3. Rogawski M. Revisiting AMPA Receptors as an Antiepileptic Drug Target. Epilepsy Currents. 2011;11(2):56-63. doi: 10.5698/1535-7511-11.2.56
  4. Hanada T, Hashizume Y, Tokuhara N et al. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331-1340. doi: 10.1111/j.1528-1167.2011.03109.x
  5. Vlasov P.N. Effektivnost' i perenosimost': rezul'taty dvoinogo slepogo platsebo-kontroliruemogo i prodlennogo otkrytogo issledovaniya otsenki dolgovremennoi bezopasnosti i effektivnosti perampanela v RF. Epilepsiya i paroksizmal'nye sostoyaniya (Spetsvypusk). 2014;10-12.(in Russ).
  6. Karlov V.A., Belyaev O.V., Vlasov P.N., Zhidkova I.A. i dr. Rossiiskii opyt primeneniya perampanela v povsednevnoi klinicheskoi praktike. Nevrologiya, neiropsikhiatriya, psikhosomatika (spetsvypusk 1). 2016;11-17. (in Russ).
  7. French J, Krauss G, Biton V et al. Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304. Neurology. 2012;79(6):589-596. doi:0.1212/wnl.0b013e3182635735
  8. French J, Krauss G, Steinhoff B et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia. 2012;54(1):117-125. doi: 10.1111/j.1528-1167.2012.03638.x
  9. Krauss G, Serratosa J, Villanueva V et al. Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408-1415. doi: 10.1212/wnl.0b013e318254473a
  10. Krauss G, Perucca E, Ben-Menachem E et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia. 2014;55(7):1058-1068. doi: 10.1111/epi.12643
  11. Steinhoff B, Ben-Menachem E, Ryvlin P et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481-1489. doi: 10.1111/epi.12212
  12. Steinhoff B, Hamer H, Trinka E et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Research. 2014;108(5):986-988. doi: 10.1016/j.eplepsyres.2014.03.015
  13. Panayiotopoulos CP. Principles of Therapy in the Epilepsies. In: Clinical Guide to Epileptic Syndromes and their Treatment. Berlin: Springer; 2007.
  14. Pylaeva O.A., Mukhin K.Yu., Petrukhin A.S. Pobochnye effekty antiepilepticheskoi terapii: diagnostika, profilaktika i terapevticheskaya korrektsiya. M.: Granat; 2016. (in Russ).
  15. Perucca P, Gilliam F. Adverse effects of antiepileptic drugs. The Lancet Neurology. 2012;11(9):792-802. doi: 10.1016/s1474-4422(12)70153-9
  16. Trinka E, Steinhoff B, Nikanorova M, Brodie M. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurologica Scandinavica. 2015;133(3):160-172. doi: 10.1111/ane.12529
  17. Lin J, Mula M, Hermann B. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. The Lancet. 2012;380(9848):1180-1192. doi: 10.1016/s0140-6736(12)61455-x
  18. Kelly K, Stephen LJ, Parker P et al. Adjunctive perampanel in highly drug-resistant localization-related epilepsy — a prospective audit. Epilepsia. 2014;55:119.
  19. Goulding P, Wright E, Geldard J et al. A service evaluation of perampanel (Fycompa) at Leeds General Infirmary. Epilepsia. 2014;55:335.
  20. Juhl S, Rubboli G. Perampanel as add-on treatment in patients with drug-resistant focal epilepsy: the clinical experience of the Danish epilepsy center. Epilepsia. 2014;55:348.
  21. Davies S, Heyman I, Goodman R. A population survey of mental health problems in children with epilepsy. Dev Med Child Neurol. 2003;45:292-295.
  22. Zhidkova I.A. Upravlenie nezhelatel'nymi yavleniyami, voznikayushchimi na fone priema perampanela. Epilepsiya i paroksizmal'nye sostoyaniya (Spetsvypusk). 2014;13-14. (in Russ).
  23. Renroe B, Yang H, Williams B. Interim efficacy and safety analysis of adjunctive perampanel in the adolescent population from the extension phase of 3 double-blind, placebo controlled phase 3 (core) studies in patients with refractory partial-onset seizures. 42nd Annual Meeting of the Child Neurology Society; 30 Oct — 2 Nov 2013; Austin, TX, USA, 2013.
  24. Mula M, Kanner A, Schmitz B, Schachter S. Antiepileptic drugs and suicidality: An expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology. Epilepsia. 2012;54(1):199-203. doi: 10.1111/j.1528-1167.2012.03688.x
  25. Cramer J. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy & Behavior. 2003;4(2):124-132. doi: 10.1016/s1525-5050(03)00005-2
  26. Mula M, Trimble M, Yuen A, Liu R, Sander J. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003;61(5):704-706. doi: 10.1212/01.wnl.0000078031.32904.0d
  27. Stephen L, Kelly K, Parker P, Brodie M. Levetiracetam monotherapy — Outcomes from an epilepsy clinic. Seizure. 2011;20(7):554-557. doi: 10.1016/j.seizure.2011.04.004
  28. Mula M, Trimble M, Lhatoo S, Sander J. Topiramate and Psychiatric Adverse Events in Patients with Epilepsy. Epilepsia. 2003;44(5):659-663. doi: 10.1046/j.1528-1157.2003.05402.x
  29. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya ot 29.06.15. Faikompa. Registratsionnyi nomer: LP-002200. Mezhdunarodnoe nepatentovannoe nazvanie: Perampanel. (in Russ).
  30. Meador K, Yang H, Piña-Garza J, Laurenza A, Kumar D, Wesnes K. Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial. Epilepsia. 2016;57(2):243-251. doi: 10.1111/epi.13279
  31. Patsalos P. Drug Interactions with the Newer Antiepileptic Drugs (AEDs). Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs. Clin Pharmacokinet. 2013;52(11):927-966. doi: 10.1007/s40262-013-0087-0
  32. Patsalos PN. Drug Interactions with the Newer Antiepileptic Drugs (AEDs). Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders. Clinical Pharmacokinetics. 2013;52(12):1045-1061. doi: 10.1007/s40262-013-0088-z
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.